



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

June 22, 2020

Neil Kumar  
Principal Executive Officer and Principal Financial Officer  
Eidos Therapeutics, Inc.  
101 Montgomery Street  
Suite 2000  
San Francisco, CA  
94104

**Re: Eidos Therapeutics, Inc.**  
**Form 10-K for the fiscal year ended December 31, 2019**  
**Filed February 26, 2020**  
**Form 10-Q for the Quarterly Period Ended March 31, 2020**  
**Filed May 8, 2020**  
**File No. 001-38533**

Dear Mr. Kumar:

We have reviewed your filing and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to these comments within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comments apply to your facts and circumstances, please tell us why in your response.

After reviewing your response to these comments, we may have additional comments.

Form 10-K for the fiscal year ended December 31, 2019

Clinical data

Phase 2 clinical trial of AG10, page 12

1. We note your reference to the most common serious adverse events on page 16. Please revise to describe all serious adverse events and disclose the frequency with which each type of serious adverse event occurred.

Item 1. Business.

Our material agreements

License agreement with Alexion, page 21

Neil Kumar  
Eidos Therapeutics, Inc.  
June 22, 2020  
Page 2

2. Please disclose the royalty rate or a range that does not exceed a 10 point range.

Form 10-Q for the Quarterly Period Ended March 31, 2020

Exhibit 31, page Ex.31

3. Please confirm that you will revise your certifications in future filings to include the form specified in Item 601(b)(31)(i) with respect to the information included in paragraph 4 of the certifications.

We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

You may contact Lisa Vanjoske at (202) 551-3614 or Mary Mast at (202) 551-3613 if you have questions regarding comments.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences